OMB # 0925-0647 Expiration Date: 1/31/2015

Medical/Behavioral Protocol Summary Form

Directions for Protocol Submission

(do not include this page with your submission)

Behavioral Exempt Protocol Submissions:

If requesting Exempt Review for a **Behavioral** research study, submit **one** completed Medical/Behavioral Protocol Summary Form (containing original signatures) the entire descriptive protocol and/or grant application and **all** instruments (survey tools), a HIPAA Summary Form (if applicable), and **two** copies of other documentation as appropriate [e.g., informed consent, assent, information sheet(s), HIPAA authorization, and advertisements] to the HIC office. There is no deadline for submission of Behavioral Exempt protocols.

Medical Exempt Protocol Submissions-Do NOT use this form:

If requesting Exempt Review for a Medical research study, submit one completed Medical Exemption Form (containing original signatures), the entire descriptive protocol and/or grant application and <u>all</u> instruments (survey tools), a HIPAA Summary Form (if applicable), and one copy of any other documentation. There is no deadline for submission of Medical Exempt protocols

Medical/Behavioral Expedited Protocol Submissions:

If requesting Expedited Review for a Medical or Behavioral research study, submit one completed Medical/Behavioral Protocol Summary Form (containing original signatures), the entire descriptive protocol and/or grant application and <u>all</u> instruments (survey tools), a HIPAA Summary Form (if applicable), and two copies of other documentation as appropriate [e.g., informed consent, assent, information sheet(s), HIPAA authorization(s), and advertisement(s)] to the HIC office. There is no deadline for submission of Expedited Protocols.

Medical/Behavioral Full Board Protocol Submissions:

If requesting Full Board Review, see the HIC website for submission deadlines.

Submit **one** copy of the Protocol Submission Checklist, manually checking each box that reflects the item(s) being submitted with this research project. Submit **20** submission packets as follows:

- 3 collated packets containing the HIC Protocol Summary Form (one copy containing original signatures), the entire descriptive protocol/grant application, investigator's (drug) brochure(s)/package insert(s), HIPAA Summary Form (if applicable) and copies of all other documentation as appropriate [e.g., informed consent, assent, information sheet(s), HIPAA authorization(s), all Instruments (survey tools), and any advertisements or flyers].
- 17 collated packets containing copies of the Protocol Summary Form, informed consent/assent/information sheet(s), non-standardized instruments (survey tools-e.g., tools developed by the PI or questionnaires/surveys that deal with sensitive subjects such as drug use or sexual practices) and any advertisements or flyers. Other documentation may be included if appropriate.

HIC Pre-Review Service (for Full Board research proposals):

For information regarding this optional service for pre-review of **Full Board** research proposals, please go to: http://www.hic.wayne.edu/hicinfo/IRBPreReviewerAnnounce.doc

NOTE: HIC responses will be forwarded by mail, email or fax to the investigator approximately 7 to 10 working days following review by the HIC/IRB. *The HIC requests that you refrain from contacting the office regarding the status of a protocol before the end of the 10 working days.*

Public reporting burden for this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0647*). Do not return the completed form to this address.

Page 1 of 21 Form Date: 04-08-09

PI Name: William Lyman

Protocol Submission Checklist

 ✓ Protocol Summary Form ✓ Appendix A (International) ✓ Appendix B (Internet) ✓ Appendix C (Minors) ✓ Appendix D (Mentally Disabled/Cognitively Impaired) ✓ Appendix E (Prisoners) ✓ Appendix F (Drugs/Devices) ✓ Appendix G (Radiation) ✓ Appendix H (Biological Specimens) 	
Letter of Support (State how many:)	
Coordinating Center Form	
☐ Debriefing script	
Materials to be distributed to participants or others: Pamphlets, brochures Books Educational/training materials Other	
Letter of Approval from a scientific review committee Protocol Review Monitoring Committee (PRMC) Clinical Investigation Committee (VAMC) Departmental Review Board (Psychiatry) MC Research Review Authorization (all research at the DMC) http://content.dmc.org/ResearchReviewProcess/	
Advertisement/Notice/Flyer: Advertisement(s) (state how many) Notice(s)/Flyer(s) (state how many)	
Consent/Assent/Information Sheet: Consent(s) (state how many2) HIPAA Authorization Form included in consent Parental Permission/Research Informed Consent (state how many Assent(s) (state how many Information Sheet(s) (state how many))
 ☐ HIPAA Summary Form☐ Grant Application/Research Protocol☐ Investigator Brochure for a drug/device☐ Package Insert(s) (state how many)	

Page 2 of 21 Form Date: 04-08-09



HIC Protocol Number

Human Investigation Committee

101 East Alexandrine Detroit, MI 48201 www.hic.wayne.edu Fax (313) 993-7122 Office (313) 577-1628

Medical/Behavioral Protocol Summary Form All HIC Submission Forms must be the current form date and typed/computer generated

	HIC Use ONLY					
	Section A: Principal Investigator (PI), Project Title & Endorsements					
1.	Name of PI:	William Lyman	Phone:	(313) 7452400	Date:	09/21/2010
	Department:	Pediatrics	Fax:	(313) 7450282		
	Division:	Children's Research Center of MI	E-mail:	wlyman@med.v	wayne.	edu
	Campus Address:	Children's Hospital of Michigan 3901 Beaubien Detroit, MI 48201	Pager:	313 247 3336		
2.	provide home mailin	students or who are not WSU faculty or employees of WSU or an affiliated health care institution must a gaddress and phone number in addition to the above information. (NOTE: If provided, all correspondence ill be sent to the home address.)				
	Home Address:		Home Phone:	()		
3.	Name of Protocol Coordinator:					N/A⊠
	Phone:	()	E-mail:			
4.	Form completed by:	William Lyman	Title:	Principal Inves	stigator	
	Phone:	(313) 7452400	E-mail:	wlyman@med	.wayne	.edu
5.	Project Title:	RT-01-M GC/MS methods to determine environmental factors on fetus and newborn				

Page 3 of 21 Form Date: 04-08-09

6. Endorsements and Financial Conflict of Interest Disclosure:

Objectivity in research is a key component of any research project. One method for maintaining objectivity is to have <u>all</u> individuals involved in research design, development, or data evaluation/analysis disclose any potential and/or real financial conflict of interest. This includes all personnel listed in response to Questions #6 and #7.

Examples of relevant relationships for potential conflict of interest include but are not limited to:

- (1) receiving past, current, or expecting future income in the form of salary, stock or stock options/warranties, equity, dividends, royalties, profit sharing, capital gain, forbearance or forgiveness of a loan, interest in real or personal property, or involvement in a legal partnership with the sponsor
- (2) receiving past, current, or expecting future income in the form of consulting fees, honoraria, gifts, gifts to the University, or payments resulting from seminars, lectures, or teaching engagements, or service on a non-federal advisory committee or review panel
- (3) serving in a corporate or for-profit leadership position, such as executive officer, board member, fundraising officer, agent, member of a scientific advisory board, member of a scientific review committee, or member of a data safety monitoring committee, regardless of compensation
- (4) inventor on a patent or copyright involving technology/processes/products licensed or expected to be licensed to the sponsor.

See HIC Policy and Procedures Institutional Review Board & Institutional and Individual Financial Conflict of Interest (COI)

7. All Investigators and other study personnel are required to take the WSU educational training program on the protection of Human Participants @ www.citiprogram.org.

Page 4 of 21 Form Date: 04-08-09

If any response below is "yes," there must be a "Financial Conflict of Interest Detailed Disclosure Form" submitted directly to the Financial Conflict of Interest Committee at the time of this protocol submission and then annually or when changes occur; if this form is **not** submitted, the protocol **cannot** be approved. The form and more information are available at: www.research.wayne.edu/coi. For additional information please contact the Conflict of Interest Coordinator, 5057 Woodward, Suite 6305, Detroit, MI 48202, Fax 313-577-2159, Phone 313-577-9064. PRINCIPAL INVESTIGATOR: For students or individuals without a WSU faculty appointment, a WSU faculty supervisor/sponsor or authorized signatory (e.g.; official from DMC, KCI, etc.) is required. Do you, your spouse or domestic partner, or any of your dependent children have a potential and/or real financial conflict of interest with the sponsor of this project, including all secondary sources? ∃ No YES In signing the description of this research project, the PI agrees to accept primary responsibility for the scientific and ethical conduct of the research, as approved by the HIC, and abide by the HIC's policies and procedures. The project cannot begin until the investigator has received documentation of HIC review and final approval. **Professor of Pediatrics** 09/21/2010 Signature of Principal Investigator Title FACULTY SUPERVISOR/SPONSOR: Do you, your spouse or domestic partner, or any of your dependent children have a potential and/or real financial conflict of interest with the sponsor of this project, including all secondary sources? $\log N$ YES Phone: Campus Address: E-mail: In signing the description of this research project, the faculty supervisor/sponsor certifies that he/she has reviewed the research plan and has approved the scientific and ethical aspects of this research. The faculty supervisor/sponsor will supervise all compliance with the HIC's guidelines. Signature of WSU Faculty Supervisor/Sponsor Printed name Title Date DEPARTMENT CHAIR/DEAN OR AUTHORIZED SIGNATORY: Do you, your spouse or domestic partner, or any of your dependent children have a potential and/or real financial conflict of interest with the sponsor of this project, including all secondary sources? YES l No In signing the submission of this research project, the Department Chair, Dean, Institute/Center Director or other authorized signatory certifies that (1) appropriate support will be provided for the research project including adequate facilities and staff, and (2) appropriate scientific and ethical oversight has been and will be provided. Bonita Stanton, MD Professor 09/21/2010 and Chair of **Pediatrics** Signature of WSU Dept Chair/Dean or authorized signatory (e.g.; official Title Printed name Date from DMC. KCI, etc.) If PI is a student, or an individual without a WSU faculty appointment, the above signature must be that of the Chair/Dean at WSU or authorized signatory (e.g.; official from DMC, KCI, etc.)

> Form Date: 04-08-09 Page 5 of 21

Briefly describe their role in the study and disclose any potential and/or real financial conflict of interest. If a response is "Yes" see previous page for additional information about the "Financial Conflict of Interest Detailed Disclosure Form."

Study personnel are persons engaged in the collection of data or have access to data through intervention or interaction with the participant, including the consent process, or have access to the participant's identifiable private information. This may include collaborators, fellows, residents, research assistants, etc.

	Name	Division/Dept	Research Role
a.	Michael Diamond	OB/GYN	Investigator
Do you, your spouse or domestic partner, or any of your dependent children have a potential and/or real financial of interest with the sponsor of this project, including all secondary sources? NO YES			
	Signature:		
b.	Alan Dombkowski	Pediatrics	Investigator
	Do you, your spouse or domestic partn of interest with the sponsor of this projection.	er, or any of your dependent children have a pote ect, including all secondary sources?	ntial and/or real financial conflict
	Signature:		1
C.	Dawn Bielawski	Pediatrics	Investigator
	of interest with the sponsor of this proje	er, or any of your dependent children have a pote ect, including all secondary sources?	ntial and/or real financial conflict
d.	Signature:	D. P	
u.	Ronald Thomas	Pediatrics	Biostatistician
	Do you, your spouse or domestic partn of interest with the sponsor of this projection.	er, or any of your dependent children have a pote ect, including all secondary sources?	ntial and/or real financial conflict
	Signature:		
e.	TBD	Pediatrics	Study Coordinator
	Do you, your spouse or domestic partner, or any of your dependent children have a potential and/or real financial conflict of interest with the sponsor of this project, including all secondary sources? No YES		
	Signature:		
f.	TBD	Pediatrics	Research Assistant
	Do you, your spouse or domestic partn of interest with the sponsor of this proje	er, or any of your dependent children have a pote ect, including all secondary sources?	ntial and/or real financial conflict
	□ No □ YES		
	Signature:		
Add	ditional study personnel list @www	w.hic.wayne.edu/hicforms/AdditionalStudy	PersonnelList.doc

Page 6 of 21 Form Date: 04-08-09

Medical/Behavioral Protocol Summary Form Medical Medical Behavioral Check the type of IRB committee 8. review. \bowtie No Yes 9. Is this request for Clinical and Translational Science Award (CTSA review)? PI must have HIC Chairman approval for CTSA review. \bowtie No Yes Is this a Clinical Trial? 10 If yes, NIH Registration number http://clinicaltrials.gov/ct2/info/about Check the applicable type of review Exempt Review * for Behavioral Research ONLY 11 being requested. Include the category for exempt or expedited (enter category #): review. (Check only one) * Guidance on review Expedited Review * for Behavioral or Medical Research categories is available at www.hic.wayne.edu/hicsub.html (enter category #): **NOTE**: For Medical EXEMPT Protocols, please use the Medical **Exemption Protocol Form.** State age range of participants' for 12 this proposed research 18to 45 a. Adult Age Range: Child (<18 years) Age 0to 18 Range: (NOTE: For research outside of Michigan, check local laws for legal definition of a "child.") Status of Principal Investigator Resident/Fellow WSU Faculty 13 (Check all that apply) VAMC Staff Graduate **DMC Staff** Undergraduate Other (explain): KCI Staff Research Proposal Master's Project Type of Project 14 Thesis/Dissertation Other (describe): # Section B: Narrative Summary 15 Provide a complete and concise description of the protocol in non-technical language (lay terms). The completed summary should be 1-3 pages in length, with up to \(^3\)4 of a page allowed for the response to each question. If the narrative summary exceeds the allowed page length, an additional page(s) can be added. **Do not 'paste'** text from the full protocol or refer to protocol page numbers. Literature citations should **not** be included in this section. The narrative summary below does not take the place of the full descriptive protocol and/or grant application.

Page 7 of 21 Form Date: 04-08-09

a.	Describe the
	background and
	rationale for the study:

The goal of this project is to determine if current technology can be used to establish whether exposure of the human fetus to a class of chemicals called phthalates, which are known to negatively affect the endocrine (hormone) system alters male sex hormone gene expression in the newborn. The basis for this research is founded on the evidence that, in animal models and in vitro tests, phthalates, which are found ubiquitously in the environment, can disrupt the endocrine system with specific effects in male neonates. Because there is mounting evidence that the prevalence of undescended testicles and abnormal penile openings are increasing in human males, this research proposal may have significant public health importance. In contrast to males, the question about the effect of phthalates on female development is less clear. Although the prevalence of abnormal early puberty in pre-teen girls is increasing, the potential relationship between this occurrence and fetal or early childhood exposure to phthalates is still to be determined. The potential impact of phthalates on human growth and development also includes its effect on metabolism as there is mounting evidence that these compounds contribute to the childhood obesity epidemic that is afflicting the United States.

Phthalates have been detected in medicines, nutritional supplements, emulsifying agents, adhesives, agricultural products, building materials, personal-care products, detergents and packaging. More importantly, phthalates are found in children's toys and alimentation products. Phthalate exposure can be through direct or by indirect routes. Diet is believed to be the most common source, with foods such as milk, butter, and meats being major sources. However, absorption through the skin and via inhalational of low-molecular-weight phthalates may occur because some phthalates are volatile. A recent study reported that the use of infant lotion, infant powder, and infant shampoo were associated with increased infant urine concentrations of phthalate metabolites. Additionally, a 2005 study reported that increased human phthalate exposure during pregnancy resulted in decreased anogenital distance between the scrotum and anus among baby boys. Phthalate metabolites were measured in urine samples collected from pregnant women and their male babies. Boys born to mothers with the highest concentrations of phthalates were 7 times more likely to have shortened anogenital distances.

b. State the goals/aims/ hypothesis for the study:

The research project is designed to determine if a combination of gas chromatography/mass spectrometry (GC/MS) and high-throughput microarray gene technology can be used efficiently in the National Children's Study (NCS) to analyze the potential effect of phthalate on fetal and newborn male gene expression.

c. List inclusion criteria:

Pregnant women who consent to this study and deliver their newborn boys at Hutzel Hospital. We will determine which woman will deliver a boy by a chart review in which there is a prenatal ultrasound that documents the sex of the fetus.

d. List exclusion criteria:

e. Describe the methods/ procedures of the study:

Women who have had a previous baby with severe endocrine abnormalities. After the women consent to the study, we will collect a sample of their urine and that of the baby before it leaves the hospital. We will also collect the foreskin after circumscion and photocopy the baby's handprint.

Section C: Research Project Characteristics

16	Check the applicable type of submission	☑ Initial Submission ☐ Resubmission of expire	d study
		HIC requested If applicable provide HIC #	
		Resubmission	
17	Funds for this project are being provided by or	Private/Pharmaceutical* WSU Institute*	
	requested from:	Industry* Drug/Device Provider*	
	Muct answer question #10	Governmental agency Departmental (WSU/DN	1C/VAMC)
	Must answer question #18	Foundation None	
		Non-Profit Organization* Other (describe):	
18	Sponsor(s):	1. Prime: National Institute of Child Health and	□ N/A
	FOR WSU Must match FES Form	Human Development	
	TON WOO Wast Material EST Offi	Subcontract from: Michigan State University)	
		2.	
		2.	
	Contact Name:	Katherine Cook	
•	Address:	301 Administration Building, MSU, E Lansing, MI	
		48824	
	Phone:	517 355 5040, ext 237	
	Grant Number:	HHS275200800007C	
	SPA Proposal Number from FES Form	00002509	
	(eight digit number)		
	If there are more than one funding source please li	st the Sponsor who is supplying the funds first	
19	Status of Funds:		□ N/A
		Pending	
20	Check all applicable performance sites where	Wayne State University: site	□ N/A
	this research will be conducted. It is essential	University Physician Group (UPG): site	
	that this information is accurate. All human research conducted at DMC, KCI or VAMC sites	☐ Kresge Eye Institute Outpatient Care	
	require authorization through their institutional		
	review process in addition to HIC approval.	Detroit Medical Center Hospital or Institute:	
		Children's Hospital of Michigan	
		Detroit Receiving Hospital/University Health Center	
		Harper University Hospital	
		Huron Valley/Sinai Hospital	
		Hutzel Women's Hospital	
		Kresge Eye Institute Operating RoomMichigan Orthopedic Specialty Surgery Hospital	
		Rehabilitation Institute of Michigan	
		Sinai-Grace Hospital	
		☐ Barbara Ann Karmanos Cancer Institute	
		John D. Dingell Veterans Administration Medical Ctr.	
		Other:	

Page 9 of 21 Form Date: 04-08-09

Section C: Research Project Characteristics

21	Provide the names of all other locations where the WSU PI will perform this research (e.g., non-UPG outpatient clinic, unaffiliated hospital(s) [e.g. other cancer centers, Henry Ford Hospital, St. Johns, etc.] school, home, church, community center, etc.). Attach a letter of support and/or IRB approval if the research is being done (1) outside of the PI's department or WSU/DMC/Practice Plans, and/or (2) at a location not affiliated with WSU.			⊠ N/A
	 Are any of the facilities/locations listed in the response to Q#21outside of the United States? 	No	Yes If checked, complete Appen complete the optional CITI r International Research, if no complete.	nodule for ot already
	E: An approval letter must accompany research from			
	ntific review committees are in place to review all res inistration Medical Center (Clinical Investigation Con			
(Dep	partmental Review Board), (3) the Karmanos Cancel	r Institute (Protocol Review Comm		
	arch, and (4) Detroit Medical Center (Research Rev	•		1/ /
22	Is this a multicenter study or clinical trial (i.e., more than one investigator at different sites, drug company study, cooperative group, etc.)?	No	☐ Yes ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐	N/A
	a. IF YES, IS WSU the Coordinating Center for this study?	No	Yes If yes, complete the Coordinat Form, available on the HIC wel include with this application.	
23	Is the local PI conducting research outside of Michigan?	No (Go to QUESTION #24)	Yes	
	If yes:			
	Does the research include adults unable to consent as participants?	□No	☐ Yes If yes, complete Appendix D	
	Does the research include children as participants?	No	Yes If yes, complete Appendix Complete the optional CITI r Research with Children/Min already complete.	nodule for ors if not
24	FOR MEDICAL RESEARCH ONLY - Is this is a treatment/intervention study?	No	Yes]N/A

Page 10 of 21 Form Date: 04-08-09

Section C: Research Project Characteristics

	 a. If Yes, describe your plan to protect and monitor the study data to ensure safety of the participants (e.g., Data Safety Monitoring Board, safety committee, PI oversight, etc.) See HIC Policy/Procedure: Data Safety Monitoring Board 					
	 Provide the name of the board, if applicable, and its contact information 					□ N/A
#	Section D: Data Collection					
25	What is the approximate number of participants/documents / specimens to be enrolled /collected?	At WSU/DMC	800	At non-WSU/DMC (e.g., multicenter sites)		
26	Prospective Data Collection Methods (Check all that apply): * If using medical records from the DMC/practice plans or a database created from medical records from the DMC/practice plans, complete a HIPAA Summary Form. FOR SOCIAL/BEHAVIORAL RESEARCH ONLY- COMPLETE THE "HIPS" MODULE FOR THE CITI TRAINING. ** Provide a copy of each data collection instrument and/or interview script with this submission. *** Audiotapes and/or videotapes can be a significant risk to the participant's	Medical Records/Database*,**** Site: Specimens**** Site: Hutzel Hospital Non-Medical Documents/Records/Database Observation of participants (i.e. their behavior) Questionnaire/Survey** Diaries** Interview** Psychological testing ** Educational testing/evaluations** Focus groups** Audio/video taping *** Internet If checked, complete Appendix B and complete the optional CITI module for Internet Research if not already complete.	□ N/A			
	confidentiality. Consequently, such materials should be destroyed at the end of the study unless specified in the consent form and the participant has given explicit permission for their retention. ****All human research conducted at DMC sites requires DMC Research Review Authorization including the use of medical records, specimens, imaging, etc http://content.dmc.org/ResearchReviewProcess/	Other (desc	cribe):			

Page 11 of 21 Form Date: 04-08-09

Section D: Data Collection Retrospective data sources Archival data**, *** Site: \times N/A (Check all that apply) ☐ Specimen repository**, *** Site: Database*,**, *** Site: * If using medical records from the Medical records/Database*, *** Site: VAMC/DMC/practice plans or a database created from medical records from the Non-Medical Documents/Records/Database*** VAMC/DMC/practice plans, complete a Internet If checked, complete Appendix B and HIPAA Summary Form. complete the optional CITI module for Internet Research if not already complete. FOR SOCIAL/BEHAVIORAL RESEARCH ONLY- COMPLETE THE "HIPS" MODULE Imaging** Site: FOR THE CITI TRAINING. Other (describe): **All human research conducted at DMC sites requires DMC Research Review Authorization including the use of medical records, specimens, imaging, etc.. http://content.dmc.org/ResearchReviewPro cess/ *** Provide a copy of each data collection instrument with this submission. 28 Identify any material(s) to be distributed to Pamphlets, brochures ⊠ N/A participants or others. Educational Materials (e.g., curriculum) **Training Materials** Provide a copy of each. Other (describe): Consent form Over what period of time will each participant 29 \bowtie N/A spend doing research-related activities? State total number of visits b. State length of each visit Less than 60 minutes State the total expected duration (including One visit only long-term follow-up) for each participant's involvement? (e.g., three 15 minute visits, two 10 minute visits for a total of 65 minutes over 2 months) Will deception or experimental manipulation be 30 \bowtie No Yes N/A used without the participant's knowledge? a. If Yes, explain why deception is necessary, describe the debriefing plan and attach a

Form Date: 04-08-09 Page 12 of 21

debriefing script.

Section D: Data Collection

31	Will a "control" group (e.g., normal healthy volunteer, participants with an absence of the condition under study, participants who are receiving standard of care, placebo or no intervention, etc.) be used in the study?	⊠ No	Yes	□ N/A
	 a. If yes, explain what is meant by "control"? See the HIC Policy/Procedure: "Vulnerable Participants: Normal Volunteers" 			
32	Indicate if any of the below apply to this research study : (Check all that apply)			
	a. Pregnant women are excluded See the HIC Policy/Procedure: "Inclusion of Pregnant Women in Research"	⊠ No	Yes	□ N/A
	If Yes, provide scientific justification			
	b. Research participants are selected based on racial/ethnic criteria	⊠ No	Yes	□ N/A
	See the HIC Policy/Procedure: "Inclusion of Women and Minorities in Research"			
	If Yes, provide justification			
	c. Research participants are selected based on gender.	☐ No	∑ Yes	∐ N/A
	See the HIC Policy/Procedure: "Inclusion of Women and Minorities in Research"			
	If Yes, provide justification	Study requires preg	nant women and male newborns	
33	Indicate if the research involves participants likely to be vulnerable to coercion or undue influence. (Check ALL that apply) See the HIC policies/procedures on vulnerable participants Complete the CITI module for the specific	weeks) * If checked for neona complete the option Involving Pregnant \	, Fetus(es), Neonates (birth to 4 Ites, complete Appendix C and al CITI module for Research Women and Fetuses in Utero rolving Children/Minors if not	□ N/A
	,			

Page 13 of 21 Form Date: 04-08-09

#	Section D: Data Collection		
	vulnerable group (www.citiprogram.org) * Not required for chart reviews. **Prisoners are defined as individuals (children or adults) who are being held in a jail, prison, or treatment facility or who have been convicted or are awaiting arraignment, trial, or sentencing. This includes those who are in hospitals, alcohol and drug treatment facilities under court order and children in detention facilities as an alternative to prison.	 ☑ Children (under 18 years of age) *If checked, please complete Appendix C and complete the optional CITI module "Research involving Children/Minors" if not already complete. If students are involved complete the optional CITI modules "Students in Research-SBR" and if applicable, "Research in Public Elementary & Secondary Schools-SBR" if not already complete. ☑ Mentally disabled/cognitively impaired adults who are unable to give consent *If checked, please complete Appendix D ☑ Prisoners **If checked, please complete Appendix E and complete the optional CITI module for Research with Prisoners if not already complete. ☑ Non-consenting participants, in emergency situations ☑ Terminally ill ☑ Other – explain 	
34	Provide specific justification for inclusion of any vulnerable participants identified in the previous question.	Need to address both prgnant women and male infants	□ N/A
35	Are students and/or employees of WSU/DMC/VAMC the target population to be enrolled in this protocol? See the HIC policy/procedures: "Vulnerable Participants: Students, Trainees and Employees" If students are involved complete the optional CITI modules "Students in Research-SBR" and if applicable, "Research in Public Elementary & Secondary Schools-SBR" if not already complete. a. If Yes, describe how the PI and/or recruiters will avoid potential coercion of	No ☐ Yes	□ N/A
	students/employees		

Page 14 of 21 Form Date: 04-08-09

Section D: Data Collection

36	How will participants be recruited? (Check all that apply) For Recruitment guidance, see HIC policy/procedures: "Recruitment of Research Participants," "Advertising for Research Participants," and "Finder's Fee." For VA Studies: recruitment of non-Veterans is allowed only when there are insufficient Veterans available to complete the study.	 ☑ Direct person-to-person solicitation ☑ Clinician/Nurse ☑ Co-Investigator/Collaborator ☑ Primary Care Provider ☐ Principal Investigator ☐ Research Nurse ☐ Research Assistant ☐ Resident/Fellow ☐ Student/Student Assistant ☐ Psychology Student Pool ☐ WSU Pipeline If checked, complete Appendix B and complete the optional CITI module for Internet Research if not already complete. ☐ Internet If checked, complete Appendix B and complete the optional CITI module for Internet Research if not already complete. ☐ Other (specify): ☐ Advertisement (state posting location and attach verbatim copies) ☐ Notice/flyer (state posting location and attach verbatim copies) 	□ N/A
37	Provide a narrative description of the recruitment procedures and informed consent process including measures to protect personal privacy. a. Describe recruitment procedures For behavioral research: note that teachers, service providers, or supervisors cannot recruit their own students, clients, employees, etc. Verify that the study introduction will include: (1) the study involves research, (2) the topic of research, (3) the time commitment required, (4) the basic procedures (e.g., interview, survey, observation, etc.) and (5) study participation is voluntary.	Dr. Diamond will review the medical record of women who arrive in the Labor and Delivery service at Hutzel to give birth. He will determine if the sex of their fetus is known. For those women who will give birth to a male baby, Dr. Diamond will approach them and tell them that we are conducting a research study which is examining the potential for environmental factors to negatively affect their male babies. Dr. Diamond will then ask if they are willing to hear about the study.	N/A

Form Date: 04-08-09

#	Section D: Data Collection		-
	b. Describe the informed consent process including measures to propersonal privacy. (Note: Consent process begins when a potential research participant is initially contacted.)	Women who have agreed to hear about the study be asked at the end of this presentation if they and their male babies would like to potentially participate. If they say yes, the approved informe consent will be given to them and they will be ask to read it, have it read to them or translated, if needed. After all of their questions about the study and related issues are answered, they will be asked sign the informed consent document.	d ked ly \square N/A
	c. If HIPAA applies (research that w accessing medical records): state will introduce the study to particip and specify their clinical relationsh any, to the participants (i.e., emploteacher, service provider, etc.)	who ants ip, if	□ N/A
	d. Describe any safeguards in place of PI and/or recruiters to protect participants likely to be vulnerable coercion or undue influence.	Participants can withdraw from the study at any ti	me no
	Section E: Consent of Research Part	icipants	1
38	Identify the personnel who will be responsible obtaining informed consent of the particip (Check all that apply). NOTE: These individuals must be among the identified as "key personnel" in question #7.	Principal Investigator Co-Investigator/Collaborator Research Nurse Research Assistant Resident/Fellow	□ N/A
		Cther (specify):	
39	Will more than one consent document (consassent, parental permission form, information be used?	on sheet)	□ N/A
	If Yes, in total how many will be us	ed?	
40	Select the type of Consent/Assent that will be NOTE: Attach copies of all consents / as	sents / information sheets / oral scripts that will be used.	□ N/A
	a. Written Consent/Parental Permiss	ion: Adult participants Parents or quardians	I

Page 16 of 21 Form Date: 04-08-09

Section E: Consent of Research Participants

	b. Assent for children	☐ Written (age 13-17)☐ Oral (age 7-12)☐ Information Sheet (age 13-17)
	c. Internet Information Sheet	Adult participants Parents or guardians If either is checked, complete Appendix B and complete the optional CITI module for Internet Research if not already complete.
	d. Information Sheet (indicate who it will be given to):	Adult participants Parents or guardians
	i. State rationale for use of an Information Sheet rather than a Written Consent.	
	Oral informed consent using a script that will be read to potential participants:	Adult participants Parents or guardians
	State rationale for use of an Oral rather than Written Consent. Describe how oral consent will be	
	documented.	
41	Will a Non-English consent/assent/information sheet be used?	No ☐ Yes ☐ N/A
	NOTE: Refer to the HIC Policy: "Informed Consent Involving Non-English Speaking Participants." If Yes, specify language(s)	
	7 3 6 7 7	
42	FOR MEDICAL RESEARCH ONLY: Is a waiver of consent for emergency situations being requested?	No
	See HIC policy available at http://www.hic.wayne.edu/HRPP_Manual/11-6_Planned_Emergency_Research.pdf	
	If Yes, explain the rationale for waiver of consent in emergency situations, and	,
43	describe the consent process. Is a waiver of consent for other reasons (e.g., chart review, database analysis) being requested?	No ☐ Yes ☐ N/A
	See federal regulations 45 CFR 46.116(d) and 46.408(c) available at www.hic.wayne.edu/hicreg.html	
	If Yes: a. Is the risk more than minimal?	□ No Yes
	b. Will the waiver adversely affect the rights and welfare of the research participants?	□ No □ Yes

Page 17 of 21 Form Date: 04-08-09

Section E: Consent of Research Participants Can the research be practicably carried out No without the waiver? Yes Will the participants be provided with No N/A additional pertinent information after l Yes participation, if appropriate? Provide protocol-specific justification for requesting a waiver of consent. Are you requesting a waiver of the \bowtie No requirement to obtain written Yes documentation of the consent process? (Consent will be obtained, but there will be no signed form documenting consent) If yes, provide a written description of the information to be provided orally to subjects. Section F: Confidentiality How will the research participants/documents/ 44 No identifier (i.e., no one can identify a specimens be identified on case report forms, participant/document/specimen from the information recorded) questionnaires, survey tools, field notes, data Go to O #45 collection tools, etc.? Coded Identifier (i.e., a code name/number that could be used to NOTE: Social Security numbers, medical

identify a participant/documents/specimens) record numbers, employee numbers, or Must answer questions a-e school identification numbers can be directly linked to individuals and must NOT be used as Each paired set of samples a code number. (maternal and newborn urine plus the foreskin and handprint) will received a unique identifier that are matched and recorded for this sample set. However, this sample set will not be linked to any hospital record or other source that could link it to a particular patient. Hence, these samples will all be anonymous. Is there a list that contains information that ⊠ No Yes can link the code name/number to a specific participant / document / specimen? If Yes:

Page 18 of 21 Form Date: 04-08-09

#	Section F: Confidentiality			j
	 a. what is the media format of the list (e.g., paper, electronic, etc.) 			
	b. Where will the list be kept?			
	c. State who will have access to the list and for what purpose.			
	 d. Describe the provisions for maintaining confidentiality, including the storage of the participants' identifiers (i.e., master list) and data (e.g., audio and video tapes). 			
	e. Describe the plans for eventual disposal of the participants' identifiers (i.e. master list) and data.			
45	Where will the original signed informed consent(s)/assent(s) be kept?			□ N/A
	NOTE: Signed consent documents cannot be stored with the master list.			
	a. State location	PI's office		
	b. State provisions for confidentiality	The file cabinet will be lo	ocked at all times	
46	Who, other than study personnel (at DMC, KCI,VA), WSU Human Investigation Committee,	Sponsor		□ N/A
	Food and Drug Administration [FDA], Office for Human Research Protections [OHRP], and/or	☐ National Cancer Institute	2	
	Office of Civil Rights [OCR] will have access to the research data? (CHECK ALL THAT APPLY)	Cooperative group		
	Other (Explain):			
47	Could any part of this research activity result in the potential identification of:			1
	a. Child/elder abuse	⊠ No	Yes*	□ N/A
	b. Reportable communicable diseases (please refer to	⊠ No	☐ Yes*	□ N/A
	http://www.michigan.gov/documents/Reportable Disease Chart 2005 122678 7.pdf			
	c. Criminal activities	No	Yes*	□ N/A
	*IF "YES", THIS MUST BE NOTED IN THE RISK SECTI			<u>, — · </u>
	NOTE: For information on obtaining a Certificat http://grants.nih.gov/grants/policy/coc/index.htm	te of Confidentiality, refer to:		

Section G: Benefits and Risks to Research Participants

#	Section G: Benefits and Risks to Research Pa	articipants			
48	Describe the benefits, if any, to the research participants for involvement in this project.*			⊠ N/A	
	(*NOTE: Financial compensation or free testing, in any form, is not a "benefit.")				
49	Describe the benefits to society (if any) that may result from participation in this research project.	associated with	ubiquitous envirnomental factor is a potentially important change in a with sexual development.	□ N/A	
50	Describe the nature and degree of potential risks to reand/or Investigator's Brochure. Do not cut and paste See Glossary under "risk" on the HIC website for a de	from the consent forn	cription of the different types of risk.		
	a. Physical*			⊠ N/A	
	b. Psychological*			⊠ N/A	
	c. Social*			⊠ N/A	
	d. Economic*			⊠ N/A	
	e. Legal*			N/A	
	* NOTE: ALL THE ABOVE IDENTIFIED RISKS AND BENEFIT	TS ARE TO BE LISTED IN	N THE INFORMED CONSENT		
51	What precautions will be taken to minimize each of the risks described above?			⊠ N/A	
# 52	Section H: Study Design Does this study provide compensation for research participants? (HIC policy available at www.hic.wayne.edu/hicpol/compens.htm) a. If Yes, describe the type and total amount of compensation and b. Specify the amount and milestone for	⊠ No	Yes	□ N/A	
	each payment:				
53	Will the research participants incur any additional expenses for experimental or protocol specific diagnostic tests or procedures? a. If Yes, explain.	⊠ No	Yes	□ N/A	
54	FOR MEDICAL RESEARCH ONLY: Will any marketed drugs, experimental/investigational drugs, chemotherapeutic drugs, biological products, recombinant DNA (plasmid or non-plasmid), infectious agents, diagnostic agents or medical devices be used?	⊠ No	Yes (Complete Appendix F)	□ N/A	

Page 20 of 21 Form Date: 04-08-09

Section H: Study Design

55	Will research participants be exposed to imaging, MRI's, PET Scans or diagnostic radiation (e.g., x-rays, CT scans, etc.)?	⊠ No	Yes (Complete Appendix G)	□ N/A
56.	Will biological specimens (e.g., blood, urine, tissue, organs, cell lines, fetal tissue, etc.) or standard of care laboratory results be used as part of this study? Refer to HIC policy on research studies involving biological specimens available at www.hic.wayne.edu/hicpol/specim.htm	□ No	Yes (Complete Appendix H)	□ N/A
57	Is a specimen repository bank being established?	□ No		□ N/A

Form Date: 04-08-09